Red blood cell-derived arginase release in hemolytic uremic syndrome.
Niklas FribergIda ArvidssonAshmita TontanahalAnn-Charlotte KristofferssonMagnus GramBernard S KaplanDiana KarpmanPublished in: Journal of translational medicine (2024)
Elevated red blood cell-derived arginase was demonstrated in HUS patients and in relevant in vivo and in vitro models. The excessively high arginase levels correlated to the degree of hemolysis and kidney dysfunction. Thus, arginase inhibition should be investigated in HUS.